Drug Profile


Alternative Names: Elitek; Fasturtec; Rasuritek; Recombinant urate oxidase - Sanofi-Aventis; SR 29142; Uricase - Sanofi-Aventis

Latest Information Update: 15 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antigouts; Oxidoreductases
  • Mechanism of Action Urate oxidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperuricaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperuricaemia

Most Recent Events

  • 14 Jul 2017 No recent reports on development identified - Registered for Hyperuricaemia (Chemotherapy-induced) in Iceland and Liechtenstein (IV,infusion)
  • 15 Mar 2016 Biomarkers information updated
  • 06 Aug 2014 Rasburicase licensed to Emcure Pharmaceuticals in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top